Connect with us

Technology

Disrupting Computational Biology: Elucidata’s AI Revolutionizes Life Sciences

Published

on

AI is transforming healthcare, paving the way for breakthroughs in precision medicine and unlocking extraordinary value. On the Disruption Interruption podcast, Elucidata CEO Abhishek Jha discusses how a data-centric approach addresses life sciences’ unique challenges. Discover the critical role of clean, structured data in driving AI-powered innovation and advancing the future of healthcare.

TAMPA BAY, Fla., Jan. 14, 2025 /PRNewswire-PRWeb/ — AI has the potential to revolutionize healthcare, with McKinsey estimating it could unlock up to $1 trillion in value across the industry. (1) This week on the Disruption Interruption podcast, host Karla Jo Helms (KJ) explores this transformative frontier with Abhishek Jha, Co-Founder and CEO of Elucidata—a biotech innovator at the intersection of AI and computational biology, driving advancements in precision medicine.

“The AI paradigm that worked for tech will not carry over to life sciences… it’s time for data-centric AI” — Abhishek Jha, Co-Founder and CEO of Elucidata

Jha sheds light on the immense opportunities AI presents while addressing critical challenges the healthcare sector must overcome to fully harness its potential. “The AI paradigm that worked for tech will not carry over to life sciences… it’s time for data-centric AI,” he asserts, emphasizing the need for a tailored approach to innovation in medicine.

Computational Biology: Simulating Science, Accelerating Discovery
Jha explains that computational biology allows researchers to simulate biological processes in the same way the aviation industry uses models to simulate flight conditions. “You cannot test your plane in every condition; it’s a very expensive and slow process,” he notes. Similarly, researchers can test and refine models before applying them in real-world experiments, making the process more efficient.

By iteratively refining these models based on experimental feedback, scientists can better understand intricate biological mechanisms. “If the model is good, you can make some predictions, go back, and test it. If not, you improve your model,” Jha illustrates.

The Trillion-Dollar Problem: Bridging the Gap Between Tech and Life Sciences
One of the most critical challenges between tech companies and life sciences is the sheer volume of data available. “They think they have a trillion-dollar problem, but they have hundreds of ten-million-dollar problems,” states Jha. As he explains, the entire paradigm must shift to adapt to a world where many valuable problems exist, rather than focusing on a singularly valuable one.

Tech giants like Google benefit from access to billions of users generating data daily, providing them with an immense pool of information to fuel AI models. In contrast, life sciences data—while equally critical—remains far scarcer and harder to obtain. For instance, even large clinical trials for widespread conditions like breast cancer typically involve only a few thousand patients, a scale that pales in comparison to the vast data sources available to tech companies.

“There’s a significant disparity,” Jha points out. “How much data about my purchasing habits is available versus my health data? We don’t have access to that, nor is it consolidated in one single place.”

Clean Data Over Big Data: The Key to AI Success
Data cleaning and preparation are often underestimated in AI workflows, particularly in life sciences. Abhishek Jha compares this to “technical debt,” where rushing to amass data without proper structuring leads to long-term challenges. For instance, inconsistent terms like “hepatitic carcinoma” and “liver cancer” across datasets create inefficiencies, forcing researchers to spend months standardizing data before analysis.

“Clean data is always more valuable than more data,” Jha emphasizes. “Investing in a thoughtful data strategy is crucial for AI success.” Without standardized terminology and organized datasets, life sciences risk delaying breakthroughs and limiting the potential of AI-driven innovation.

Links
Disrupting Drug Development Delays: How Abhishek Jha’s Elucidata Is Powering Faster Medical Advances with AI
https://omny.fm/shows/disruption-interruption/disrupting-drug-development-delays-how-abhishek-jh

LinkedIn: https://www.linkedin.com/in/abhishek-jha-ba20a821/
Company Website: https://www.elucidata.io/
Disruption Interruption is the podcast where you will hear from today’s biggest Industry Disruptors. Learn what motivated them to bring about innovation and how they overcame opposition to adoption.
Disruption Interruption can be listened to in Apple’s App Store and Spotify.

About Disruption Interruption™
Disruption is happening on an unprecedented scale, impacting all manner of industries— MedTech, Finance, IT, eCommerce, shipping, logistics, and more—and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, “THAT’S IT! I’VE HAD IT!”? Time to Disrupt and Interrupt with host Karla Jo “KJ” Helms, veteran communications disruptor. KJ interviews badasses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits—and not-so-common—that are changing our economic markets… and lives. Visit the world’s key pioneers that persist to success, despite arrows in their backs at http://www.disruption-interruption.com.

About Abhishek Jha
Abhishek Jha is the Co-Founder and CEO of Elucidata, a trailblazing biotech company recognized as one of Fast Company’s Most Innovative Biotech Companies of 2024. Under his leadership, Elucidata has transformed biological discovery by leveraging data-centric approaches and cutting-edge AI and ML innovations.
Elucidata’s flagship platform, Polly, accelerates research by harmonizing multi-modal biomedical data—such as Omics, Assay, Real-World, Clinical, EHR, and CRO data—into a Unified Data Model. Polly’s LLM-powered curation enables 10x faster data preparation with 99.99% accuracy, drastically reducing the time to actionable insights and advancing precision medicine.
Before founding Elucidata in 2015, Abhishek spent nearly six years as a Senior Scientist at Agios Pharmaceuticals, contributing to the development of four first-in-class drugs. His experience includes designing algorithms to integrate high-throughput metabolic data with transcriptional data and deploying visualization tools for clinical applications.
Abhishek holds a Postdoctoral Fellowship from MIT, where he developed computational models in immunology, and his career has been defined by a passion for combining technology and science to revolutionize patient outcomes. Beyond his professional pursuits, Abhishek enjoys discussing innovations in biotech and mentoring the next generation of entrepreneurs.

About Karla Jo Helms
Karla Jo Helms is the Chief Evangelist and Anti-PR® Strategist for JOTO PR Disruptors™. Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line — and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill into the good graces of public opinion — Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception.

References
1. Bhasker, Shashank, et al. “Tackling Healthcare’s Biggest Burdens with Generative AI.” mckinsey.com, 10 July 2023, http://www.mckinsey.com/industries/healthcare/our-insights/tackling-healthcares-biggest-burdens-with-generative-ai.

Media Inquiries:
Karla Jo Helms
JOTO PR™
727-777-4629

Media Contact

Karla Jo Helms, JOTO PR™, 727-777-4629, khelms@jotopr.com, jotopr.com

View original content to download multimedia:https://www.prweb.com/releases/disrupting-computational-biology-elucidatas-ai-revolutionizes-life-sciences-302350601.html

SOURCE Disruption Interruption

Continue Reading

Technology

Finloop Becomes Industry Pioneer in HKMA’s EnsembleTX, Exploring Compliant Tokenisation Applications

Published

on

By

HONG KONG, Nov. 3, 2026 /PRNewswire/ — Finloop Finance Technology Holding Limited (“Finloop”), an AI-driven global one-stop Web5 (Web2+Web3) wealth technology platform, today announced that it has become an industry pioneer in EnsembleTX, launched by Hong Kong Monetary Authority (HKMA), to explore faster, more transparent, and more efficient settlement of real-value tokenised transactions.

HKMA launched the Project Ensemble sandbox in August 2024 to accelerate adoption of tokenisation. In November 2025, it introduced EnsembleTX, marking the commencement of the pilot phase of Project Ensemble. This represented a significant advancement in enabling real-value transactions involving tokenised deposits and digital assets within a controlled pilot environment. In its initial phase, EnsembleTX focuses on empowering market participants to utilise tokenised deposits in tokenised money market fund transactions, and to manage liquidity and treasury needs in real time. Moving forward, EnsembleTX will further support the interbank settlement of tokenised deposit transactions in tokenised Central Bank Money (CeBM) on a 24/7 basis. 

Finloop has built FinRWA Platform (FRP), Asia’s first one-stop RWA (Real-World Asset) technology, issuance, and distribution platform. The platform supports multi-party participation across the full lifecycle of tokenisation, involving issuers, custodians, tokenisation agents, and other institutions. Finloop has achieved several industry breakthroughs in the tokenisation sector, including supporting the distribution of multi-currency tokenised funds and launching Hong Kong’s first technical solution for a unit trust tokenised fund. Finloop has also advanced RWA projects spanning cultural and creative IPs, gold mines, oil and gas fields, and automobiles, leveraging digital assets to empower the real economy. Its subsidiary is also an authorised distributor of the regulated Hong Kong dollar stablecoin HKDAP. Through its integration into the EnsembleTX, Finloop will draw on its technology solutions that bridge Web2 and Web3 to support the compliant and efficient issuance and distribution of tokenised assets among institutions.

Cai Hua, Chief Executive Officer of Finloop, said: “Finloop is honored to participate in the HKMA’s EnsembleTX. Hong Kong is at the forefront globally in the regulatory foresight and ecosystem development of digital assets and RWAs. Finloop will fully leverage its core strengths in tokenisation technology and institutional-grade wealth technology, actively follow the guidance of regulators, and work closely with tokenised deposit banks and other industry pioneers. We aim to provide institutional clients with a secure, compliant, transparent, and efficient trading experience for tokenised assets, and jointly expand Hong Kong’s tokenisation ecosystem.”

Looking ahead, Finloop plans to build on its practical experience in EnsembleTX to actively explore a broader range of compliant use cases, including tokenised money market funds, tokenised ETFs, tokenised private funds, tokenised notes, and related treasury management. It will continue to leverage its technological advantages in connecting Web2 and Web3 to drive the efficient issuance, distribution, trading, and settlement of relevant tokenised assets among institutions, further advancing the development of Hong Kong’s tokenisation ecosystem.

About Finloop Finance Technology Holding Limited

Finloop Finance Technology Holding Limited, along with its subsidiaries (collectively referred to as “Finloop”), is an AI-driven global one-stop Web5 (Web2+Web3) wealth technology platform located in Hong Kong. Finloop offers comprehensive wealth management products and technology solutions to various financial institutions. Its offerings include cash management, mutual funds, alternatives, structured products, bonds, insurance, and virtual assets. As a fintech leader in Asia during the Web3 wave, Finloop has focused on bridging physical and digital assets, developing a one-stop RWA technology, issuance and distribution platform to pioneer new growth pathways in the wealth management industry. For more information, visit www.finloop.hk and www.finlooprwa.com

Follow Finloop on LinkedIn and X for the latest updates. 

View original content:https://www.prnewswire.com/apac/news-releases/finloop-becomes-industry-pioneer-in-hkmas-ensembletx-exploring-compliant-tokenisation-applications-302927192.html

SOURCE Finloop Finance Technology Holding Limited

Continue Reading

Technology

Xinhua Silk Road: Foreign journalists explore Yuhang’s innovation-driven development

Published

on

By

BEIJING, Nov. 3, 2026 /PRNewswire/ — Journalists from South Korean, Turkish, U.S. and Cuban media outlets visited several hi-tech companies and modern agricultural demonstration parks in Yuhang District, Hangzhou, on October 26-28.

Through site visits and hands-on experiences, they gained firsthand insights into Yuhang’s progress in integrating technological and industrial innovation.

They began their tour at Scantech, a leading comprehensive 3D solutions provider, where they explored and experienced 3D visual digitization technologies on October 26.

After trying out a 3D scanner, Isaura Diez, a journalist with Cuba’s Prensa Latina news agency, said this was her first time using a scanner, and was deeply impressed by both the device and the technology behind it. What particularly impressed her were its wide-ranging applications, including in the medical and industrial fields, she added.

On October 27, the group visited RoboCT Technology, a national high-tech enterprise dedicated to the development and application of exoskeleton robotics, to learn about the research, development and practical applications of exoskeleton robots.

At RoboCT, they learned how exoskeletons help patients with lower-limb impairments from spinal cord injuries and strokes stand and walk again, and saw brain-computer interface technology enabling thought-controlled rehabilitation.

After trying on the GoGo-H Pro exoskeleton, a reporter from Turkish newspaper Aydinlik praised the equipment for its incredibly light weight. It felt just like a part of my own body, he said, adding that what impressed him was experiencing firsthand how China’s advanced technologies are being used to improve people’s lives.

At Xynova, a leading supplier of key components in the humanoid robotics sector, Dan Sandoval, a contract photographer of the Associated Press, put on its high-DoF dexterous hand product Flex 2. He said the product could perform all the movements that a human hand can make and he hoped to see it applied in an increasingly wide range of scenarios in the future.

The journalists later visited the Qianxi eco-friendly agricultural demonstration park in Jingshan Town. There, they learned how digital rice seedling cultivation and AI-powered management systems are being applied throughout the entire rice production process.

As Hangzhou’s new urban center, Yuhang is advancing technological and industrial integration, driving momentum in the digital economy, cutting-edge technologies, urban-rural development and rural revitalization. 

Original link: https://en.imsilkroad.com/p/352790.html

SOURCE Xinhua Silk Road

Continue Reading

Technology

Oracle Announces Pricing of $20 Billion of Common Stock and Senior Notes

Published

on

By

AUSTIN, Texas, Nov. 2, 2026 /PRNewswire/ — Oracle Corporation (NYSE: ORCL) today announced the pricing of concurrent underwritten public offerings of 86,206,897 shares of its common stock, par value $0.01 per share, at a public offering price of $116.00 per share (the “common stock offering”) and $2,000,000,000 of its 7.000% notes due 2029, $1,750,000,000 of its 7.450% notes due 2031, $2,250,000,000 of its 7.850% notes due 2033, $2,500,000,000 of its 8.000% notes due 2037 and $1,500,000,000 of its 8.650% notes due 2046 (the “notes offering” and, together with the common stock offering, the “offerings”).

Each of the offerings is expected to close on November 4, 2026, subject to customary closing conditions. The completion of the common stock offering is not contingent on the completion of the notes offering, and the completion of the notes offering is not contingent on the completion of the common stock offering.

The net proceeds from the common stock offering will be approximately $9.9 billion, after deducting the underwriting discounts and Oracle’s estimated offering expenses. The net proceeds from the notes offering will be approximately $10.0 billion, after deducting the underwriting discounts and Oracle’s estimated offering expenses.

The net proceeds of the offerings, if completed, will be used for general corporate purposes, which may include capital expenditures, repayment of indebtedness, future investments or acquisitions and payment of cash dividends on or repurchases of our common stock.

BofA Securities is acting as sole global coordinator of the offerings. Wells Fargo Securities, Citigroup, BNP PARIBAS, Deutsche Bank Securities, J.P. Morgan, PNC Capital Markets LLC, Goldman Sachs & Co. LLC, HSBC and SMBC Nikko are acting as joint book-running managers of the offerings. BTIG is a joint book-running manager of the common stock offering. U.S. Bancorp is a joint book-running manager of the notes offering. Lloyds Securities is a joint book-running manager of the notes offering and a co-manager of the common stock offering. Intesa Sanpaolo, Mizuho, MUFG, TD Securities, Santander, BNY Capital Markets, CIBC Capital Markets and ING are acting as co-managers of the offerings. Standard Chartered Bank is a co-manager of the notes offering.

Registration Statement and Prospectus

Oracle has filed a registration statement on Form S-3 (including a prospectus) with the Securities and Exchange Commission (“SEC”) for the offerings to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents Oracle has filed with the SEC for more complete information about Oracle and the offerings. The offerings may be made only by means of a prospectus supplement and accompanying prospectus. Copies of the registration statement, preliminary prospectus supplement and accompanying prospectus related to each of the offerings can be obtained by visiting the SEC’s website at https://www.sec.gov or by contacting BofA Securities, Inc., Telephone: 1-800-294-1322.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor does it constitute an offer, solicitation or sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration and qualification under the securities laws of such state or jurisdiction.

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.

“Safe Harbor” Statement: Statements in this press release relating to the anticipated use of the net proceeds from the offerings; our ability to complete the offerings on the anticipated timeline or at all; and other characterizations of future events and circumstances are “forward-looking statements” and are subject to material risks and uncertainties. All information set forth in this press release is current as of November 2, 2026. Oracle undertakes no duty to update any statement in light of new information or future events.

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-announces-pricing-of-20-billion-of-common-stock-and-senior-notes-302927244.html

SOURCE Oracle

Continue Reading

Trending